0001209191-22-059727.txt : 20221205
0001209191-22-059727.hdr.sgml : 20221205
20221205165753
ACCESSION NUMBER: 0001209191-22-059727
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221201
FILED AS OF DATE: 20221205
DATE AS OF CHANGE: 20221205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Grant Julie Papanek
CENTRAL INDEX KEY: 0001673237
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40431
FILM NUMBER: 221445671
MAIL ADDRESS:
STREET 1: 2765 SAND HILL ROAD
CITY: MENLO PARK
STATE: CA
ZIP: 94025
FORMER NAME:
FORMER CONFORMED NAME: Grant Papanek Julie
DATE OF NAME CHANGE: 20210518
FORMER NAME:
FORMER CONFORMED NAME: Papanek Julie
DATE OF NAME CHANGE: 20160427
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Day One Biopharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001845337
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 832415215
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2000 SIERRA POINT PARKWAY, SUITE 501
CITY: BRISBANE
STATE: CA
ZIP: 94080-1930
BUSINESS PHONE: 650 484-0899
MAIL ADDRESS:
STREET 1: 2000 SIERRA POINT PARKWAY, SUITE 501
CITY: BRISBANE
STATE: CA
ZIP: 94080-1930
FORMER COMPANY:
FORMER CONFORMED NAME: Day One Biopharmaceuticals Holding Co LLC
DATE OF NAME CHANGE: 20210209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-01
0
0001845337
Day One Biopharmaceuticals, Inc.
DAWN
0001673237
Grant Julie Papanek
2000 SIERRA POINT PARKWAY, SUITE 501
BRISBANE
CA
94080
1
0
0
0
Common Stock
2022-12-01
4
S
0
4760
21.7213
D
414598
I
See Footnote
Common Stock
2022-12-01
4
S
0
240
22.3375
D
414358
I
See Footnote
Common Stock
2022-12-02
4
S
0
5000
21.5452
D
409358
I
See Footnote
Common Stock
2358
I
See Footnote
Common Stock
2548403
I
See Footnote
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2021.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.25 to $22.24 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or for any other purpose.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.29 to $22.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.99 to $21.87 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents shares held by The Adam and Julie Grant Revocable Trust dtd October 13, 2017 of which the Reporting Person and her spouse are co-trustees. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose.
Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose.
/s/ Charles N. York II, Attorney-in-Fact
2022-12-05